<DOC>
	<DOCNO>NCT02163018</DOCNO>
	<brief_summary>Currently , effective causal treatment peanut allergy . A chemically modify , aluminium hydroxide adsorb peanut extract ( HAL-MPE1 ) subcutaneous administration develop . Results vitro vivo preclinical study demonstrate immunotherapeutic potential HAL-MPE1 . Therefore , phase I , single-centre clinical trial design assess safety tolerability HAL-MPE1 peanut allergic patient .</brief_summary>
	<brief_title>HAL-MPE1 First-in-human</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>1 . Signed informed consent . 2 . Male female subject age 1865 year . 3 . A welldocumented medical history systemic reaction ingestion peanut 4 . Positive food challenge ≤1.5 gram peanut protein ingestion within last 2 year 5 . Positive serum specific antipeanut Ara h 2 Immunoglobulin E ( IgEtest ) ( &gt; 0.7 kiloUnits ( kU ) /L ) within last 2 year 6 . Forced expiratory volume one second ( FEV1 ) &gt; 70 % predict value 1 . Subjects history severe anaphylaxis peanut follow symptom : hypotension , hypoxia , neurological compromise ( collapse , loss consciousness incontinence ) challenge peanut . 2 . Baseline serum tryptase level &gt; 20 µg/l 3 . Known allergy know hypersensitivity ( placebo ) excipients 4 . Participation interventional study aim desensitize peanut allergy past 5 . Any specific immunotherapy ( SCIT , SLIT OIT ) study period 6 . Severe immune disorder ( include autoimmune disease ) and/or disease require immunosuppressive drug 7 . Significant active malignancy malignant disease within past 5 year 8 . Severe uncontrolled disease could increase risk patient participate study , include limited : severe unstable lung disease ; endocrine diseases ; clinically significant renal hepatic disease , haematological disorder ; severe ongoing symptomatic allergic diseases 9 . History cardiovascular disease , uncontrolled hypertension arrhythmias 10 . Diseases contraindication use adrenaline ( e.g . hyperthyroidism , glaucoma ) 11 . Use systemic steroid within 4 week start study study 12 . Treatment βblockers/ACE inhibitor 13 . Vaccination within one week start therapy study 14 . AntiIgE/antiTumor necrosis factor ( TNF ) therapy biologic immunomodulatory therapy within 6 month prior inclusion study 15 . Participation clinical study new investigational drug within last 3 month biological within last 6 month prior study 16 . Pregnancy ( test perform screening ) , lactation inadequate contraceptive measure woman childbearing age ( contraceptive measure consider adequate : intrauterine device , hormonal contraceptive , contraceptive pill , implant , transdermal patch , hormonal vaginal device injection prolong release ) 17 . Alcohol , drug medication abuse within past year 18 . Any clinically significant abnormal laboratory parameter screen 19 . Lack expect lack cooperation compliance 20 . Severe psychiatric , psychological , neurological disorder 21 . Patients employee sponsor , institution 1st grade relative partner investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>